Ferinject

Fe deficiency when oral Fe prep are ineffective or cannot be used; there is a clinical need to deliver Fe rapidly.

IV Individualized dosage. Max single dose: 1,000 mg. Max recommended cumulative dose: 1,000 mg once a wk. Patient w/ haemodialysis-dependent CKD Max single daily dose: 200 mg.

Hypersensitivity. Anaemia not attributed to Fe deficiency. Evidence of Fe overload or disturbances in Fe utilisation.

Do not administer by SC or IM route. Closely observe patients for signs & symptoms of hypersensitivity during & for at least 30 min following each administration. Stop treatment immediately if hypersensitivity reactions or signs of intolerance occur; risk of progression to Kounis syndrome. Possible transient & w/o clinical symptom hypophosphataemia. Risk of hypophosphataemia osteomalacia is rare as frequency is unknown, adverse drug reactions exclusively reported in post-marketing setting. Patients receiving multiple higher doses as part of long-term treatment & who have underlying risk factors (eg, vit D deficiency, Ca & phosphate malabsorption, secondary hyperparathyroidism, hereditary haemorrhagic telangiectasia, inflammatory bowel disease & osteoporosis) should be monitored for hypophosphataemic osteomalacia including serum phosphate control. Re-evaluate treatment in case of persistent hypophosphataemia. Acute or chronic infection; patients w/ history of asthma, eczema, other atopic allergies or allergic reactions to other parenteral Fe prep. Discontinue use in patients w/ ongoing bacteraemia. Discontinue use immediately in case of paravenous leakage. 1 mL of undiluted Ferinject contains Na 5.5 mg. Avoid in patients w/ hepatic dysfunction. Patients w/ haemodialysis-dependent CKD receiving single dose of >200 mg Fe. Pregnancy & lactation. Transient foetal bradycardia may occur; carefully monitor unborn baby during administration. Not recommended in childn <14 yr.

Hypophosphataemia; headache, dizziness; flushing, HTN; nausea; inj/infusion site reactions. Rarely, anaphylactoid/anaphylactic reactions.

Concomitant use w/ oral Fe therapy (if required, do not start oral Fe therapy for at least 5 days after the last administration of Ferinject).

Vitamins & Minerals (Pre & Post Natal) / Antianemics

B03AC - Iron, parenteral preparations ; Used in the treatment of anemia

POM